apricus wealth LLC Has $520,000 Position in Abbott Laboratories (NYSE:ABT)

apricus wealth LLC increased its stake in shares of Abbott Laboratories (NYSE:ABT) by 17.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 4,594 shares of the healthcare product maker’s stock after buying an additional 699 shares during the period. apricus wealth LLC’s holdings in Abbott Laboratories were worth $520,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Future Financial Wealth Managment LLC bought a new position in Abbott Laboratories during the 3rd quarter worth $31,000. Peterson Financial Group Inc. acquired a new position in shares of Abbott Laboratories during the 3rd quarter worth approximately $32,000. Valued Wealth Advisors LLC raised its position in shares of Abbott Laboratories by 78.4% in the third quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock valued at $33,000 after buying an additional 127 shares in the last quarter. Highline Wealth Partners LLC bought a new stake in shares of Abbott Laboratories in the third quarter valued at approximately $37,000. Finally, JDM Financial Group LLC increased its stake in Abbott Laboratories by 51.3% during the 3rd quarter. JDM Financial Group LLC now owns 363 shares of the healthcare product maker’s stock worth $41,000 after acquiring an additional 123 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ABT shares. Wells Fargo & Company increased their price objective on shares of Abbott Laboratories from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday. Stifel Nicolaus boosted their price objective on shares of Abbott Laboratories from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday. UBS Group lifted their price target on Abbott Laboratories from $146.00 to $148.00 and gave the company a “buy” rating in a research note on Thursday. Evercore ISI raised their price objective on Abbott Laboratories to $136.00 and gave the company a “buy” rating in a research note on Thursday, January 2nd. Finally, Oppenheimer initiated coverage on Abbott Laboratories in a research note on Tuesday, October 8th. They set an “outperform” rating and a $130.00 target price for the company. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $132.50.

Abbott Laboratories Stock Up 1.5 %

Shares of NYSE:ABT opened at $125.12 on Friday. The firm has a fifty day moving average of $115.07 and a 200 day moving average of $113.15. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $125.67. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The firm has a market capitalization of $217.01 billion, a PE ratio of 16.36, a price-to-earnings-growth ratio of 2.51 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.34. The company had revenue of $10.97 billion during the quarter, compared to the consensus estimate of $11,029,400 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. Abbott Laboratories’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.19 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.15 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, January 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.89%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.55. Abbott Laboratories’s payout ratio is currently 30.85%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.